A New Hope for Progeria – CRISPR gene therapy could slow down accelerated aging and improve life expectancy

The CRISPR gene therapy for Hutchinson Gilford Progeria

Researchers at the Salk Institute are one step closer to developing a therapy for Hutchinson Gilford progeria, a rare genetic condition that can be described as accelerated ageing, because people with this disorder appear to age much faster than usual. Researchers at the Salk Institute were able, using a CRISPR/Cas9 genetic therapy, to slow the rate of the disease, improve health and extend lifespan in a mouse.

What is Hutchinson Gilford progeria (HGP)?

A mutation in the LMNA genes causes progeria, a degenerative disease. The disease is characterized by an early onset, rapid progression, and symptoms similar to normal aging. However, the timeframe of progeria is much faster, resulting in a drastically shorter life expectancy. The average lifespan of a human with progeria is only 13 years.


Leave a Reply

Your email address will not be published. Required fields are marked *